A 22-month-old female with a past medical history significant for cutaneous candida infections, thrush, pneumonia, otitis media, and bronchitis presented with a primarily skin fold eruption associated with intense pruritus that has been worsening over the past 6 months. She was born full-term to healthy, nonconsanguineous parents. Per parents, the patient has been sick "all the time." She started having cutaneous candida infections shortly after birth, 2 episodes of thrush in infancy, pneumonia requiring hospitalization for intravenous antibiotics and supplemental oxygen at 6 months, and multiple episodes of otitis media, and bronchitis. She was up-to-date with her vaccinations and has had normal growth and development since birth.
Family history was significant for similar findings in her 2 older sisters, mom, maternal aunt, and 3 cousins. Her mom also experienced episodes of thrush, primarily in her childhood, cutaneous candida infections, esophageal strictures, and nail dysplasia. The mother denied history of endocrine disorders in herself or family members who have similar cutaneous candida infections. Prior to our patient's birth, her 2 sisters and mother underwent genetic evaluation, but had been lost to follow-up in another city after redeployment in the military.
On examination, patient was happy, interactive, and overall healthy-appearing. Erythematous plaques with pearl white scales were identified on her plantar surfaces bilaterally as well as in the skin folds of the axilla and perineum (Figure 1 ). In addition, the patient had multiple individual flesh-colored dome-shaped papules with surrounding erythema. Her 2 female siblings had similar findings while her mother was noted to have hyperkeratotic nails and generalized erythroderma ( Figure 2 ).
Final Diagnosis
Chronic mucocutaneous candidiasis.
Clinical Course
The potassium hydroxide (KOH) test from a skin scraping of the patient's inguinal fold revealed pseudohyphae and budding yeast cells, indicative of cutaneous infection with Candida albicans (Figure 3 ). Laboratory testing of complete blood cell count, immunoglobulin levels, flow cytometric assessment of T-cell and B-cell populations, neutrophil function, and mitogen stimulation were all within normal limits. Specific lymphocyte proliferation response to C albicans was absent. An abnormal low response to tetanus toxoid was observed; however, antibody titer response to tetanus vaccination was normal. Genetic sequencing identified a heterozygous R274Q mutation in STAT1. Prior records revealed that her mother and sisters also had gainof-function mutations in the signal transducer and activator of transcription 1 (STAT1) gene.
The patient's disease manifestation was primarily cutaneous in her intertriginous regions. Her course was also complicated by superficial infections with methicillin-sensitive Staphylococcus aureus and molluscum contagiosum as well as scabies. She did not have any autoimmune abnormalities. Her cutaneous fungal infection was treated with oral itraconazole, clotrimazole 1% cream, and triamcinolone 0.1% cream while oral ivermectin was required for eradication of scabies. For her superficial staphylococcal infection, she received 2 courses of cephalexin followed by prophylactic dosing with sulfamethoxazole/trimethoprim. She clinically improved with the above therapeutic regimens with subsequent yeast screens remaining negative.
Discussion
Chronic mucocutaneous candidiasis (CMC) describes a highly heterogeneous group of disorders characterized by recurrent infections in mucous membranes, skins, and nails caused by Candida.
1,2 A common immunologic finding seen in these patients is deficient T-cell mediated cytokine production to provide cell-mediated immunity to Candida. Early evidence for this immunologic basis of CMC came from observations of patients with DiGeorge syndrome and severe combined immunodeficiency (SCID). These patients commonly had chronic candidiasis of their oral mucosa, skin, and nails and were found to have low numbers of circulating T lymphocytes as well as poor lymphocyte proliferation to stimulation with Candida.
2 CMC is associated with both acquired and inherited conditions. Examples of acquired medical conditions that result in CMC include human immunodeficiency virus (HIV), diabetes mellitus, and use of antibiotics or immunosuppresants.
1 Oral candidiasis in HIV-infected patients is in fact thought to be a significant prognostic marker for progression to acquired immunodeficiency syndrome. 2 CMC is also seen as part of various inherited clinical conditions associated with gene defects leading to deficient T-cell mediated production of interleukin-17 (IL-17) ( Table 1) . Patients with autosomal dominant hyper IgE syndrome (AD-HIES), associated with a mutation in the signal transducer and activator of transcription 3 (STAT3) gene, present with CMC and increased susceptibilities to cutaneous and pulmonary staphylococcal diseases. 3 Patients with autoimmune polyendocrinopathy candidiasis ectodermal dysplasia (APECED), an autosomal recessive disorder associated with mutations in the autoimmune regulator (AIRE) gene, present with CMC and multiple autoimmune endocrinopathies, such as hypoparathyroidism, adrenal insufficiency, and type 1 diabetes mellitus. 4 Patients with homozygous caspase recruitment domain-containing protein 9 (CARD9) deficiency have CMC and increased susceptibilities to dermatophytoses and Candidal meningitis. As in the case of our patient, CMC can also be seen as a part of CMC disease (CMCD), an autosomal dominant disorder associated with a point mutation of STAT1. CMCD presents with primarily CMC without other overt clinical manifestations. 6, 8 Individuals with STAT1 GOF mutations however also have increased susceptibilities to viral and bacterial infections, such as molluscum contagiosum and S aureus, failure to thrive, dysphagia/esophageal stenosis, autoimmune diseases such as hypothyroidism, cerebral aneurysms, and carcinomas. 6 Some of the associated phenotypes, such as cerebral aneurysm, can lead to poor outcomes and even early death. Hence, these patients should be cared for at multidisciplinary centers with familiarity in the diagnosis and management of CMC. 6 Our patient presented with mucocutaneous fungal infections with Candida albicans and superficial infections with S aureus and molluscum contagiosum. Patient's mother had esophageal stenosis and nail dysplasia, which are also findings associated with CMCD. She and her family members did not manifest noninfectious phenotypes associated with CMCD such as autoimmune conditions or failure to thrive.
Our patient's specific genetic mutation, R274Q, was first characterized in 2011 as one of the STAT1 mutant alleles resulting in CMCD. The mutation affects the coiled-coil domain involved in nuclear dephosphorylation and dimerization of unphosphorylated STAT1. 9 Further experiments suggested that the hyperphosphorylated state of the mutant STAT1 inhibits IL-12R/IL-23R signaling, leading to decreased Th1/Th17 responses and thus, an increased susceptibility to fungal infections. 10 Patients confirmed to have the mutation to this point were found to have clinical features of CMC and the most common nonfungal phenotype seen within the group was thyroid autoimmunity, which is consistent with what has been reported for the general population of patients carrying the STAT1 GOF mutation. 6 When evaluating patients with recurrent infections with Candida, secondary immunodeficiencies due to underlying disease states, such as HIV or diabetes mellitus, should be considered. Additionally, immunologic work-up should be performed to assess for immune dysfunction and to identify any primary or secondary immune abnormalities. 2 Genetic testing for known genes associated with CMC, such as STAT3, AIRE, CARD9, and STAT1, may also be valuable in elucidating other CMC-associated clinical conditions. For certain genetic disorders associated with CMC, endocrinopathies are common and therefore, should be screened for regularly. 2 As CMCD is one of the genetic disorders associated with endocrinopathies, our patient will be referred to endocrinology for screening. 6 She will also continue to be co-managed with Pediatric Dermatology, Allergy and Immunology, and Pediatric Infectious Disease. The first-line therapy for patients with CMC is long-term treatment with antifungals, such as ketoconazole, fluconazole, itraconazole, and terbinafine, and prompt identification and treatment of any associated comorbid conditions. 2 Our patient has had negative yeast screens on oral itraconazole and clotrimazole cream. The high rate of azole resistance may however necessitate use of alternative antifungals such as amphotericin B and echinocandin. 6 Prophylactic antibiotic therapy may also be required for recurrent bacterial infections, particularly with S aureus. Treatment with granulocyte colony stimulating factors (GM-CSF) and Ruxolitinib, an oral Janus kinase (JAK) inhibitor, have been shown to be beneficial in some patients with difficult-to-treat CMC. 11, 12 Bone marrow transplantation has been attempted but is not considered a standard treatment option at this present time.
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Conclusion
Chronic mucocutaneous candidiasis is a heterogeneous clinical entity caused by deficiencies, acquired or inherited, affecting T-cell mediated production of cytokines, namely IL-17. We discussed the case of a 22-month-old female who presented with a flare of her cutaneous candidiasis with superimposed cutaneous infections with S aureus and molluscum contagiosum found to have an R274 variant of the STAT1 gene, indicative of chronic mucocutaneous candidiasis disease. Her sisters and mother had similar clinical phenotypes and genetic findings. Our patient is currently doing well with oral itraconazole, oral sulfamethoxazole/trimethoprim, and clotrimazole cream and will continue to have close follow-up from multidisciplinary teams for management of the various facets of CMCD.
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